These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17574313)

  • 1. Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data.
    Tapiainen T; Prevots R; Izurieta HS; Abramson J; Bilynsky R; Bonhoeffer J; Bonnet MC; Center K; Galama J; Gillard P; Griot M; Hartmann K; Heininger U; Hudson M; Koller A; Khetsuriani N; Khuri-Bulos N; Marcy SM; Matulionyte R; Schöndorf I; Sejvar J; Steele R;
    Vaccine; 2007 Aug; 25(31):5793-802. PubMed ID: 17574313
    [No Abstract]   [Full Text] [Related]  

  • 2. Inadvertent inoculation as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Wenger P; Oleske JM; Kohl KS; Fisher MC; Brien JH; Graham PL; LaRussa PS; Lipton S; Tierney B;
    Vaccine; 2007 Aug; 25(31):5754-62. PubMed ID: 17537553
    [No Abstract]   [Full Text] [Related]  

  • 3. Robust take following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data.
    Graham PL; LaRussa PS; Kohl KS;
    Vaccine; 2007 Aug; 25(31):5763-70. PubMed ID: 17537551
    [No Abstract]   [Full Text] [Related]  

  • 4. Eczema vaccinatum as an adverse event following exposure to vaccinia virus: case definition & guidelines of data collection, analysis, and presentation of immunization safety data.
    Nell P; Kohl KS; Graham PL; LaRussa PS; Marcy SM; Fulginiti VA; Martin B; Trolin I; Norton SA; Neff JM;
    Vaccine; 2007 Aug; 25(31):5725-34. PubMed ID: 17532547
    [No Abstract]   [Full Text] [Related]  

  • 5. Progressive vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data.
    Nell P; Kohl KS; Graham PL; LaRussa PS; Marcy SM; Fulginiti VA; Martin B; McMahon A; Norton SA; Trolin I;
    Vaccine; 2007 Aug; 25(31):5735-44. PubMed ID: 17540484
    [No Abstract]   [Full Text] [Related]  

  • 6. Generalized vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Beigel J; Kohl KS; Brinley F; Graham PL; Khuri-Bulos N; LaRussa PS; Nell P; Norton S; Stoltman G; Tebaa A; Warschaw K;
    Vaccine; 2007 Aug; 25(31):5745-53. PubMed ID: 17537552
    [No Abstract]   [Full Text] [Related]  

  • 7. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Rüggeberg JU; Gold MS; Bayas JM; Blum MD; Bonhoeffer J; Friedlander S; de Souza Brito G; Heininger U; Imoukhuede B; Khamesipour A; Erlewyn-Lajeunesse M; Martin S; Mäkelä M; Nell P; Pool V; Simpson N;
    Vaccine; 2007 Aug; 25(31):5675-84. PubMed ID: 17448577
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
    Wise RP; Bonhoeffer J; Beeler J; Donato H; Downie P; Matthews D; Pool V; Riise-Bergsaker M; Tapiainen T; Varricchio F;
    Vaccine; 2007 Aug; 25(31):5717-24. PubMed ID: 17493712
    [No Abstract]   [Full Text] [Related]  

  • 9. Rash including mucosal involvement: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
    Beigel J; Kohl KS; Khuri-Bulos N; Bravo L; Nell P; Marcy SM; Warschaw K; Ong-Lim A; Poerschke G; Weston W; Lindstrom JA; Stoltman G; Maurer T;
    Vaccine; 2007 Aug; 25(31):5697-706. PubMed ID: 17403561
    [No Abstract]   [Full Text] [Related]  

  • 10. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data.
    Kohl KS; Walop W; Gidudu J; Ball L; Halperin S; Hammer SJ; Heath P; Varricchio F; Rothstein E; Schuind A; Hennig R;
    Vaccine; 2007 Aug; 25(31):5858-74. PubMed ID: 17548132
    [No Abstract]   [Full Text] [Related]  

  • 11. Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
    Kohl KS; Walop W; Gidudu J; Ball L; Halperin S; Hammer SJ; Heath P; Hennig R; Rothstein E; Schuind A; Varricchio F;
    Vaccine; 2007 Aug; 25(31):5839-57. PubMed ID: 17553602
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatigue: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
    Jones JF; Kohl KS; Ahmadipour N; Bleijenberg G; Buchwald D; Evengard B; Jason LA; Klimas NG; Lloyd A; McCleary K; Oleske JM; White PD;
    Vaccine; 2007 Aug; 25(31):5685-96. PubMed ID: 17400340
    [No Abstract]   [Full Text] [Related]  

  • 13. Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
    Jorch G; Tapiainen T; Bonhoeffer J; Fischer TK; Heininger U; Hoet B; Kohl KS; Lewis EM; Meyer C; Nelson T; Sandbu S; Schlaud M; Schwartz A; Varricchio F; Wise RP;
    Vaccine; 2007 Aug; 25(31):5707-16. PubMed ID: 17408816
    [No Abstract]   [Full Text] [Related]  

  • 14. Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
    Kohl KS; Ball L; Gidudu J; Hammer SJ; Halperin S; Heath P; Hennig R; Labadie J; Rothstein E; Schuind A; Varricchio F; Walop W;
    Vaccine; 2007 Aug; 25(31):5821-38. PubMed ID: 17540485
    [No Abstract]   [Full Text] [Related]  

  • 15. Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
    Halperin S; Kohl KS; Gidudu J; Ball L; Hammer SJ; Heath P; Hennig R; Labadie J; Rothstein E; Schuind A; Varricchio F; Walop W;
    Vaccine; 2007 Aug; 25(31):5803-20. PubMed ID: 17548135
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of gender on reporting of MMR adverse events in Saudi Arabia.
    Khalil MK; Al-Mazrou YY; Al-Ghamdi YS; Tumsah S; Al-Jeffri M; Meshkhas A
    East Mediterr Health J; 2003; 9(1-2):152-8. PubMed ID: 15562745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany.
    Schlipköter U; Mühlberger N; von Kries R; Weil J
    Infection; 2002 Dec; 30(6):351-5. PubMed ID: 12478324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation.
    Marcy SM; Kohl KS; Dagan R; Nalin D; Blum M; Jones MC; Hansen J; Labadie J; Lee L; Martin BL; O'Brien K; Rothstein E; Vermeer P;
    Vaccine; 2004 Jan; 22(5-6):551-6. PubMed ID: 14741143
    [No Abstract]   [Full Text] [Related]  

  • 19. Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design.
    Park T; Ki M; Yi SG
    Stat Med; 2004 Jun; 23(12):1871-83. PubMed ID: 15195321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.
    Bonhoeffer J; Menkes J; Gold MS; de Souza-Brito G; Fisher MC; Halsey N; Vermeer P;
    Vaccine; 2004 Jan; 22(5-6):557-62. PubMed ID: 14741144
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.